Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Anti-lymphocyte-depleting antibodies have increasingly been utilized in the clinic as induction therapy aiming to improve transplantation outcomes by reducing the need for long-term immunosuppression. However, maintenance immunosuppression is still required as lymphocyte reconstitution through homeostatic proliferation, partially driven by IL-7, continues to replenish tolerance-refractory immune cells capable of rejection. In murine models of MHC mismatched skin grafting, we investigated whether it is feasible to control the lymphocyte reconstitution process to delay rejection and favor tolerance processes. We found that a short course of anti-IL-7 receptor blocking antibody following T cell depletion, combined with the mammalian target of rapamycin inhibitor Rapamycin, could significantly delay graft rejection in one mouse strain, and achieve transplantation tolerance in another. The combination treatment was found to delay T cell reconstitution and, in the short term, enriched for Foxp3+ regulatory T cells (Tregs), at the expense of effector cells. Extended graft survival and tolerance were dependent on TGF-ß, indicating a role for induced Tregs. These findings point to the feasibility of building on lympholytic induction by guiding early lymphocyte reconstitution to favor endogenous regulatory mechanisms.

Original publication

DOI

10.1111/ajt.12756

Type

Journal article

Journal

Am J Transplant

Publication Date

07/2014

Volume

14

Pages

1678 - 1689

Keywords

Campath, IL-7, homeostatic proliferation, rapamycin, transplantation tolerance, Animals, Antibodies, Monoclonal, Antigens, CD, Antigens, Neoplasm, CD52 Antigen, Female, Glycoproteins, Graft Rejection, Graft Survival, Immunosuppressive Agents, Lymphocyte Depletion, Male, Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, Mice, Inbred CBA, Mice, Transgenic, Receptors, Interleukin-7, Sirolimus, Skin Transplantation, T-Lymphocytes, Regulatory, Transforming Growth Factor beta, Transplantation Tolerance